BTCC / BTCC Square / Global Cryptocurrency /
Guardant Health Stock Surges 30% on Strong Earnings and Raised Guidance

Guardant Health Stock Surges 30% on Strong Earnings and Raised Guidance

Published:
2025-10-30 20:11:02
13
2
BTCCSquare news:

Guardant Health shares skyrocketed 30% following a robust third-quarter earnings report and upward revision of full-year revenue projections. The precision oncology firm reported $265.2 million in Q3 revenue, marking a 39% year-over-year increase, with its cancer screening segment showing particular strength.

Positive free cash FLOW arrived ahead of schedule, while the net loss of $0.74 per share beat analyst expectations. The company now anticipates full-year revenue between $965-$970 million, up from previous guidance of $915-$925 million, signaling accelerating growth across its oncology and biopharma divisions.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.